COMPANY:

Roche

"These infections can be difficult to detect due to nonspecific symptoms and have high morbidity and mortality.Case Report The patient is a 41-year-old male with a history of non-ischemic cardiomyopathy with LVAD placement (2015) complicated by chronic driveline infection status post 3 HTs: first in 2017 with antibody mediated rejection requiring ECMO/ATG/IVIG/PLEX/bortezomib; then in 2020 with early vasculopathy treated with multivessel PCI and tocilizumab; third HT in 6/2025. Findings were consistent with a ruptured mycotic aneurysm.Summary Antifungal prophylaxis in HT recipients is only administered in specific case scenarios and not universally. This case suggests that re-do HT recipients, given their cumulative immunosuppression exposure, may also benefit from fungal prophylaxis."

"He received ATG induction and cyclosporine (neurologic side effects with tacrolimus), mycophenolate mofetil (MMF), and prednisone taper for maintenance...He was subsequently transitioned from cyclosporine to everolimus...His tacrolimus was transitioned to sirolimus...His MMF was discontinued, and he is currently undergoing R-CHOP.Summary Recipients of HLT may face a higher risk of developing PTLD compared to those who receive single-organs. Larger, more comprehensive studies are necessary to confirm this observed trend and modifiable risk factors. If confirmed, HLT pts could potentially benefit from reduced immunosuppression regimen, leveraging immunologic tolerance associated with liver transplantation."

P1/2 | "Early MR (by C2D1) was achieved in 35% of patients and strongly associated with improved rPFS and OS while PSA50 responses by C2D1 were not observed in any patients. The rPFS benefit of adding olaparib to radium-223 appeared more evident in those who achieved a MR. Early on treatment ctDNA dynamics in bone-dominant mCRPC may be a valuable tool for treatment decisions with radium-223 therapy."

"Descriptive statistics were used to describe safety endpoints (cytokine release syndrome [CRS], immune effector cell– associated neurotoxicity syndrome [ICANS], cytopenia) and HCRU (tocilizumab/steroid use, hospitalization). In this retrospective RW analysis, liso-cel demonstrated similar effectiveness and a more favorable safety and HCRU profile versus axi-cel as a 2L therapy for R/R LBCL. Despite limited follow-up, these RW findings suggest liso-cel could deliver safety advantages without compromising efficacy in a broad population of patients with 2L LBCL. 1 ."

"One patient with FGFR1 fusion was treated with pemigatinib and achieved a CR for over 3 years. One patient with TRAF mutation obtained a CR after treatment with rituximab...Our institutional data, along with findings from the existing literature, suggest that AXG may have a distinct molecular profile compared to other HNs. A deeper understanding of its mutational landscape may offer insights into disease biology and identify therapeutic targets."

P3 | "Fixed duration Lonca-R showed no new safety signals and demonstrated encouraging antitumor activity, with signs of durable response in 4 patients who maintained CR for >28 months after EOT. Lonca-R resulted in lower median Cmax than monotherapy in C1. CD19 staining was not predictive of efficacy."

P1 | "Lonca-Glofit in R/R B-NHL showed a manageable/consistent safety profile and encouraging efficacy in heavily-pretreated aggressive lymphoma patients. Results suggest Lonca complements Glofit's mechanism and provides additive efficacy.Results previously presented: EHA 2025."

"Many OA receive non-anthracycline based treatment(tx), or attenuated regimens (i.e. R-miniCHOP) to avoid toxicity. Despite significant comorbidity and ahigh prevalence of factors associated with STox, events were less common than expected in this group.De-escalation of therapy appears feasible for pts with interim uMRD/PET- response, limiting toxicitywithout impacting long-term outcomes. These findings suggest that SD R-CHOP warrants further study infrail OA with DLBCL at high risk for STox."